Teclison Ltd.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.teclison.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
- Conditions
- Colorectal Cancer; Lung Cancer
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT04701476
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
🇨🇳China Medical University Hsinchu Hospital, Hsinchu, Taiwan
🇨🇳Chung Shan Medical University Hospital, Taichung, Taiwan
Combination of TATE and PD-1 Inhibitor in Liver Cancer
- Conditions
- Hepatocellular CarcinomaGastric Cancer
- Interventions
- Combination Product: Trans-arterial tirapazamine embolization
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT03259867
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
TATE Versus TACE in Intermediate Stage HCC
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03145558
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸Oregon Health Science University, Portland, Oregon, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- Conditions
- Hepatocellular CarcinomaGastrointestinal Cancer MetastaticNeuroendocrine Tumors
- Interventions
- Procedure: Conventional Transarterial Embolization (TAE)
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02174549
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States